China Probiotics Q1 2024: Adjuvant Therapy and Oral Health

Newer data: Probiotics Expand Beyond GI: Emotional Wellness Surges 160%

Executive Summary#

While China's probiotics health supplement market came under pressure in Q1 2024, a clear structural shift was under way inside it. Three functional segments, adjuvant therapy (+101.9% YoY), oral health (+80.2% YoY) and mood regulation (+64.1% YoY), grew strongly by targeting specific health conditions, while most probiotics are sold on general wellness. This companion article to our pillar analysis, China Probiotics E-Commerce Q1 2024: Condition-Led Growth, looks at the brand strategies and pricing behind each of these segments on two leading Chinese marketplaces in Q1 2024.

Adjuvant Therapy More Than Doubles on IBS-Focused Products#

Adjuvant therapy probiotics, which are products positioned to support the treatment of gastrointestinal conditions and in particular irritable bowel syndrome (IBS), generated CN¥ 6.69M in Q1 2024 sales, more than doubling with growth of 101.9% YoY. The revenue base is still small, but we believe the segment's growth and the kind of brands selling in it point to a commercially significant emerging market.

International specialist brands are prominent in the category, and their products are built around specific conditions and strains. Lifesflora (舒伯特) sells its "Dr. Gut" amino acid probiotic glutamine powder, positioned on IBS and intestinal nutrition; PrecisionBiotics (普葆) sells a B. longum 35624 chewable tablet, and Morinaga (森永) its BB536 probiotic capsule.

Adjuvant Therapy Segment Structural Features#

• International brands: Most of the larger brands in the segment are international, and they bring clinical positioning and strain-level claims (BB536, B. longum 35624) that Chinese consumers associate with pharmaceutical-grade efficacy.
• Premium pricing: Adjuvant therapy is one of the two highest-priced probiotics segments, together with mood regulation, which reflects both multi-pack bundling and the premium consumers are willing to pay for condition-specific products.
• Growth across several brands: Several specialist brands recorded triple-digit growth, which indicates that the segment's growth is lifting a number of specialists at once and is not concentrated in a single brand.

Oral Health Grows 80.2% as New Consumers Arrive#

The oral health probiotics segment reached CN¥ 24.1M in Q1 2024 revenue, up 80.2% YoY, while volume grew 147.0%, well ahead of revenue, which is a clear sign that the segment is gaining new consumers at lower price points.

Oral Health Brand Archetypes#

• Social-commerce natives (Earth Park, WOEF JO, Gold Partner): built for content-driven discovery on short-video and social content platforms, typically at a lower ASP
• Supplement brand extensions (Swisse, Life Space, WonderLab): drawing on established brand equity and flagship store infrastructure on established marketplaces, typically at a higher ASP

Oral Health Market Positioning

The market ASP of CN¥ 133.6, the lowest among the health supplement segments, together with volume growth of 147%, confirms that oral health probiotics are in a phase of acquiring new consumers, in which accessibility and awareness come before premiumisation.

Mood Regulation: Anxiety-Driven Positioning Supports Premium Pricing#

Mood regulation probiotics grew 64.1% YoY to CN¥ 5.5M in Q1 2024, with products aimed at children, students and adults who have difficulty sleeping. The segment's ASP of CN¥ 341.7 reflects the premium that consumers are willing to pay for products positioned on anxiety and cognitive performance.

Brands in this segment use messaging built on anxiety about the "inability to concentrate on study or work" and the "inability to fall asleep". They position probiotics as a stress-management tool for consumers in China who are under academic and professional pressure. Brands cite the gut-brain axis, the scientific framework that links the health of the gut microbiome to mental well-being, to give these products a clinical framing that supports their premium pricing.

The segment is still too new for detailed brand-level analysis, but its growth of 64.1% and its premium ASP indicate strong product-market fit and significant room to expand as consumers learn more about the gut-brain connection.

ASP Differences Show How Mature Each Segment Is#

Average selling prices across the eight functional segments show a clear gradient of maturity:

• Premium, early-stage segments (adjuvant therapy, and mood regulation at CN¥ 341.7) keep high ASPs, supported by condition-specific positioning and limited competition
• Mid-range segments (beauty and anti-ageing at CN¥ 249.3, women's intimate care at CN¥ 246.8, immune regulation at CN¥ 208.7) sit in the established middle ground with moderate competition
• Mass-market segments (gut health at CN¥ 135.2, oral health at CN¥ 133.6) have lower ASPs, driven by competition on volume and by strategies to acquire new consumers

Average selling prices came down in most segments, and most of all in oral health, which is consistent with rapid volume-led growth drawing in lower-priced entrants. The exception is anti-H. pylori, where the ASP rose 17.6% while sales came under pressure, which suggests that the segment is narrowing to a smaller and more premium core.

Key Takeaways#

• Adjuvant therapy probiotics grew 101.9% YoY to CN¥ 6.69M, in a premium-priced segment where international IBS specialists are prominent.
• Oral health probiotics grew 80.2% YoY to CN¥ 24.1M, with volume up 147%, as social-commerce-native brands built on content-driven discovery entered the segment.
• Mood regulation probiotics grew 64.1% YoY to CN¥ 5.5M, at a premium ASP of CN¥ 341.7, with gut-brain axis positioning for anxiety and sleep.
• Brand strategies divide between social-commerce-native newcomers and extensions of established supplement brands.
• ASPs reflect how mature each segment is, as early-stage segments price at a premium while mass-market segments converge towards CN¥ 130-135.

About the Data#

This analysis is based on Moojing Market Intelligence data covering Q1 2024 (January-March 2024) on two leading Chinese marketplaces. Brand-level analysis covers the larger brands in each featured segment^[1].